Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hims & Hers Health Inc (NY: HIMS ) 23.84 -0.54 (-2.20%) Streaming Delayed Price Updated: 3:40 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Hims & Hers Health Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > 10 Health Care Stocks Whale Activity In Today's Session June 13, 2024 Via Benzinga 8 Analysts Assess Hims & Hers Health: What You Need To Know June 13, 2024 Via Benzinga Chart Of The Day: Hims & Hers Health - Good Growth In Good Sex June 12, 2024 Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. Via Talk Markets Looking Into Hims & Hers Health's Recent Short Interest June 07, 2024 Via Benzinga EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In May: Where Do Nvidia, Tesla, GameStop, AMC Rank? June 07, 2024 Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Via Benzinga Looking At Hims & Hers Health's Recent Unusual Options Activity May 31, 2024 Via Benzinga Smart Money Is Betting Big In HIMS Options May 29, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session June 03, 2024 Via Benzinga Kimberly-Clark To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday June 03, 2024 Via Benzinga Hims & Hers Health Stock Soared This Week: Here's Why June 01, 2024 The company is still riding momentum from its recent weight loss drug announcement. Via The Motley Fool SPDR ETF Report For Thursday, May 30 May 31, 2024 In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Thursday, May 30. Via Talk Markets Topics ETFs Unpacking the Latest Options Trading Trends in Hims & Hers Health May 23, 2024 Via Benzinga Navigating 10 Analyst Ratings For Hims & Hers Health May 22, 2024 Via Benzinga Hims & Hers Is Changing the Game May 22, 2024 GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption. Via The Motley Fool SPDR ETF Report For Wednesday, May 29 May 30, 2024 In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Wednesday, May 29. Via Talk Markets Topics ETFs SPDR ETF Report For Tuesday, May 28 May 29, 2024 In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Tuesday, May 28. Via Talk Markets Topics ETFs A New Name in Weight Loss Drugs May 28, 2024 Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. Via The Motley Fool Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now? May 28, 2024 Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. Via The Motley Fool The Ultimate Growth Stock to Buy With $20 Right Now May 26, 2024 I challenge you to name another $20 stock with more long-term potential. Via The Motley Fool 7 Stocks to Dominate in the Next Economic Upturn May 24, 2024 Discover the top stocks to buy for the next economic upturn, carefully selected for their robust growth potential. Via InvestorPlace Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon. May 23, 2024 The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders. Via InvestorPlace The Growth Stock Shuffle: 2 to Ditch and 1 to Own May 22, 2024 Investing in growth stocks requires a keen eye for profitability. Ditch these two unprofitable stocks and embrace this telehealth winner. Via InvestorPlace EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic May 21, 2024 Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." Via Benzinga Topics ETFs Meme Stocks GameStop, AMC Fade In Interest After Roaring Kitty Exit: Here's What WallStreetBets Is Eyeing Next May 21, 2024 Retail traders could be shifting away from meme stocks to several other stocks seeing strong interest on WallSteetBets. Via Benzinga HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections May 20, 2024 HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. Via InvestorPlace Tech Surge Boosts Nasdaq To Record Highs May 20, 2024 The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. Via Talk Markets Topics Stocks Exposures US Equities Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday? May 20, 2024 Wall Street rallies on Monday as major US indices reach fresh record highs. Metal commodities surge, Treasury yields stay stable. Cruise stocks soar. Via Benzinga Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 20, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session May 20, 2024 Via Benzinga Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars May 20, 2024 Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.